Abstract

Nonalcoholic fatty liver disease (NAFLD) is the number one cause of chronic liver disease worldwide, with 25% of these patients developing nonalcoholic steatohepatitis (NASH). NASH significantly increases the risk of cirrhosis and decompensated liver failure. Past studies in rodent models have shown that glycine-N-methyltransferase (GNMT) knockout results in rapid steatosis, fibrosis, and hepatocellular carcinoma progression. However, the attenuation of GNMT in subjects with NASH and the molecular basis for its impact on the disease process is still unclear. To address this knowledge gap, we show the reduction of GNMT protein levels in the liver of NASH subjects compared to healthy controls. To gain insight into the impact of decreased GNMT in the disease process, we performed global label-free proteome studies on the livers from a murine modified amylin diet-based model of NASH. Histological and molecular characterization of the animal model demonstrate a high resemblance to human disease. We found that a reduction of GNMT leads to a significant increase in S-adenosylmethionine (AdoMet), an essential metabolite for transmethylation reactions and a substrate for polyamine synthesis. Further targeted proteomic and metabolomic studies demonstrated a decrease in GNMT transmethylation, increased flux through the polyamine pathway, and increased oxidative stress production contributing to NASH pathogenesis.

Highlights

  • Nonalcoholic fatty liver disease (NAFLD) is an excess buildup of fat in the liver and is the leading cause of chronic liver disease worldwide

  • Multiple studies have shown that GNMT mRNA levels are decreased in nonalcoholic steatohepatitis (NASH) subjects, and there is a negative correlation between the severity of liver damage and GNMT expression [10,11]

  • We developed and validated a targeted mass spectrometry method using selected reaction monitoring (SRM) to identify and quantitate liver GNMT in NASH and healthy subjects

Read more

Summary

Introduction

Nonalcoholic fatty liver disease (NAFLD) is an excess buildup of fat in the liver and is the leading cause of chronic liver disease worldwide. NASH is characterized by hepatocellular damage involving steatosis, inflammation, and liver fibrosis. It is a significant risk factor for cirrhosis and hepatocellular carcinoma, and it significantly increases the risk of death due to liver-related causes [1,2]. GNMT KO animals spontaneously develop steatosis around three months of age and inflammation and fibrosis of the liver at eight months [7,8]. These studies indicated GNMT KO results in a significant increase in liver AdoMet that is directly responsible for steatosis and fibrosis. We show that GNMT downregulation reduces transmethylation activity and increases flux into polyamine metabolism using targeted proteomics and metabolomics. This study provides key insights into metabolic changes in the liver contributing to a cytotoxic environment and NASH pathogenesis

GNMT Is Downregulated in Human NASH
Dysregulated AdoMet Metabolism in NASH
Animal Studies
Histology and NAS Scoring
Global Mass Spectrometry Analysis
Bioinformatic Analysis
Targeted Mass Spectrometry Analysis
HNE Immunofluorescence
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call